The Quantellect read.As of Nov 19, 2026, 6 active firms cover Tvardi Therapeutics, Inc: 4 rate it Buy or better, 1 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. The target range is very wide, $3.00 to $14.00 (about 4.7x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $7.33 sits 612% above the current $1.03. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.33 next quarter toward $-1.65 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Neutral
Strong Buy00%
Buy467%
Neutral117%
Sell117%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$7.33
+612.0% upside
Average target across 6 active firms as of Nov 19, 2026 vs $1.03 current
Highest Target$14.00
Average Target$7.33
Lowest Target$3.00
Detailed analyst forecasts for TVRD
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 4 of 6 active firms rate TVRD a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TVRD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.33
Range $-0.50 – $-0.11 · 5 analysts
Next period, 5 analysts expect Tvardi Therapeutics, Inc. to earn $-0.33 a share (range $-0.50 – $-0.11), versus — a year earlier. Full-year consensus is $-2.27, growing to $-1.65 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Tvardi Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TVRD.
#1
Julian Harrison
BTIG · Rank #183
Buy
$5.00+385.4% to target
Overall win rate
41%
+ Follow
#2
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$13.00+1162.1% to target
Overall win rate
30%
+ Follow
#3
Jay Olson
Oppenheimer · Rank #484
Buy
$10.00+870.9% to target
Overall win rate
31%
+ Follow
#4
Etzer Darout
Barclays
Sell
$3.00+191.3% to target
Coverage
—
+ Follow
#5
Ryan Deschner
Raymond James
Buy
$10.00+870.9% to target
Coverage
—
+ Follow
TVRD stock forecast FAQ
What is TVRD's average 12-month price target?+
The 6 active firms with a live target average $7.33 for Tvardi Therapeutics, Inc. over the next 12 months, ranging from a $14.00 high to a $3.00 low, as of Nov 19, 2026.
Is TVRD stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 6 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 1 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TVRD?+
The Street-high target is $14.00 (LUCID CAPITAL MARKETS), and the Street-low is $3.00 (Barclays). The average of all 6 active-firm targets is $7.33.
How many active Wall Street firms cover TVRD?+
6 active firms have a recognized rating on Tvardi Therapeutics, Inc. as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TVRD?+
Among analysts who currently cover TVRD, Julian Harrison of BTIG has the strongest overall Quantellect track record (Rank #183). Their current call is Buy with a $5.00 target.
What is Tvardi Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.33 per share (range $-0.50 – $-0.11) across 5 analysts. Full-year EPS is projected at $-2.27, rising to $-1.65 the following year.
How much revenue is Tvardi Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading TVRD lately?+
As of Nov 19, 2026, 4 of 6 active firms rate TVRD a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TVRD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.